FIELD: biochemistry.
SUBSTANCE: invention refers to an isolated antibody or its antigen-binding fragment which specifically binds CD73, as well as to a pharmaceutical composition containing it. Also disclosed is a method of treating using said antibody or fragment thereof.
EFFECT: invention enables effective treatment of an individual identified as having a tumor characterized by high expression of CD73.
25 cl, 33 dwg, 17 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY TO HUMAN CD73 | 2017 |
|
RU2754058C2 |
| CD73 BLOCKING ANTIBODIES | 2020 |
|
RU2819204C2 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
| MOLECULES OF ANTIBODIES TO CD73 AND THEIR APPLICATION WAYS | 2018 |
|
RU2791192C2 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| ANTIBODIES AGAINST STAPHYLOCOCCUS AUREUS LEUKOTOXINS | 2019 |
|
RU2805969C2 |
